An observational study in Immunoglobulin Prophylaxis, Cytomegalovirus Infections and Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Antonello Di Paolo, M.D., Ph.D.. Recruiting at 1 site in Italy. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by Antonello Di Paolo, M.D., Ph.D. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Cytomegalovirus Infections with a site in Italy — 5 open to participants now, 6 under way, 1 of them phase 3. Cytomegalovirus Infections · Italy.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 18th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →5 of the 18 studies in Cytomegalovirus Infections with a site in Italy are open now. Recruiting first, the newest first:
MSD Italia S.r.l. · Sites in Italy
Ages 0–18
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy, United States, Belgium and 6 more countries
Ages 18+
Fondazione IRCCS Policlinico San Matteo di Pavia · Sites in Italy
Ages 18+
Tobias Feuchtinger · Sites in Italy, Belgium, France and 3 more countries
Ages 2 mo+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 1 Month to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 10 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 93 observational studies indexed under Cytomegalovirus Infections.
Median enrollment 326 across the 14 interventional studies, 177 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Antonello Di Paolo, M.D., Ph.D. as lead sponsor.
Antonello Di Paolo, M.D., Ph.D. has 1 study filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Cytomegalovirus Infections with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05234723IRCCS Azienda Ospedaliero-Universitaria di BolognaGanciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients | 2027-02-28 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Cytomegalovirus Infections with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Human cytomegalovirus (CMV) is a globally prevalent, human-specific herpesvirus characterised by a lifelong latency after primary infection, an often asymptomatic reactivation and affecting up to 100% of adults based on region and age. CMV reactivation has serious risks for immunocompromised patients, especially those undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In these patients, CMV can lead to graft failure, multiorgan disease, increased risk of other infections, GVHD, post-transplant lymphoproliferative disorders, and higher transplant-related mortality (TRM). Although antiviral prophylaxis, CMV infection occurs in 38-80% of HSCT recipients, but current antiviral drugs are insufficiently effective and they are associated with adverse effects. Furthermore, treatment failure is due to the high genetic variability of CMV. The protective role of virus-specific antibodies remains under debate. Some studies suggest that high neutralizing antibody titers protect transplant recipients from CMV, while others highlight the importance of T-cell responses. However, recent animal studies showed that humoral immunity alone can prevent CMV reactivation, even without T or NK cells. In solid-organ transplant patients, antibody titers ≥480 have been linked to reduced infection, shorter treatment, and full protection from CMV disease. Although the use of anti-CMV immunoglobulin remains controversial, the IRCCS Burlo Garofolo has used it as post-transplant prophylaxis and second-line treatment for over a decade.
The main objective of their study was to assess whether CMV-specific immunoglobulin prophylaxis reduces CMV incidence and severity in pediatric HSCT patients. Secondary goals included evaluating its effect on transplant outcomes and its efficacy across different ethnic groups. A population pharmacokinetic (POP/PK) study was also conducted to better understand the drug's distribution and elimination and to identify factors influencing its pharmacokinetics in patients.
The study will enroll all patients who received standard myeloablative conditioning. GVHD prophylaxis consisting of tacrolimus and, for unrelated donors, rabbit ATG and mycophenolate mofetil. Haploidentical transplants initially used in vivo T-cell depletion with post-transplant cyclophosphamide, later replaced by ex vivo αβ+/CD19+ T-cell depletion.
Outcomes included overall survival (OS), relapse-related mortality (RRM), and GVHD, defined by standard grading systems. Immune reconstitution was measured by CD4+ T-lymphocyte counts, with ≥500 cells/μL in two readings within 100 days post-HSCT considered adequate. Follow-up continued until death or last contact, with a minimum duration of 12 months for survivors.
Viral Load Detection
CMV DNAemia was quantified in whole blood using real-time PCR (CMV ELITe MGB Kit). Monitoring occurred twice weekly during hospitalization, then weekly in outpatient visits until immune reconstitution and end of immunosuppression.
CMV-Specific Immunoglobulin Prophylaxis and Treatment
Prophylaxis was administered using Cytomegatect® (Biotest Pharma GmbH), beginning on day 3 of conditioning and continued biweekly during hospitalization. Post-discharge, it was given at each hospital admission until CD4+ normalization. If DNAemia appeared, a 3-5 day "boost" treatment was given based on risk assessment. Non-responders (based on viral load behavior) discontinued treatment. In cases of CMV disease, dosing and treatment duration were tailored. Cytomegatect was dosed by weight: 1000 U (\<10 kg), 2000 U (10-25 kg), 3000 U (25-50 kg), and 4000 U (>50 kg).
Foscarnet was used as first-line therapy within the first post-transplant month. Ganciclovir or valganciclovir was introduced after engraftment. Second-line options included cidofovir, letermovir, and maribavir. Advanced therapies involved NK or CD45RO+ lymphocyte infusions. CMV IgG levels were monitored 24-72 hours after each infusion for inpatients and before administration for outpatients.
CMV-Related Complications
CMV-related complications were classified per Ljungman et al.'s updated definitions. CMV infection referred to virus detection in body fluids or tissues. DNAemia denoted CMV DNA presence in blood. Primary infection was the first detection in previously unexposed patients; recurrent infections occurred after a 4-week CMV-negative interval. Refractory infections showed persistent or increasing viral load despite at least two weeks of treatment. CMV disease followed existing consensus criteria.
Statistical and POP/PK Analyses
Continuous variables were summarized by means or medians with interquartile ranges, depending on distribution (tested via Shapiro-Wilk). Categorical variables were presented as counts and percentages. Group comparisons were performed using chi-square tests for qualitative variables and Wilcoxon tests for continuous ones. Kaplan-Meier curves and log-rank tests assessed survival outcomes. Differences in pharmacokinetics between occasions were evaluated with ANOVA.
Plasma concentrations of anti-CMV immunoglobulin were analyzed using a nonlinear mixed-effects modeling approach via Monolix 2023.1. Mono-, bi-, and tri-compartmental models with various error structures were evaluated. Covariates (age, weight, creatinine clearance) were assessed for influence on model performance, which was judged based on objective function value (OFV), standard errors, and residual distributions. Individual elimination half-lives were calculated as t½ = (0.693 × Vi) / Cli, where Vi and Cli are individual volume of distribution and clearance values
Children who underwent allogeneic HSCT due to any condition
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric allo-HSCT recipients who have not received CMV-specific immunoglobulin prophylaxis after transplantation.
Pediatric allo-HSCT recipients who received an anti-CMV prophylaxis with immunoglobulin (Megalotect)
Biological: Anti-CMV immunoglobulins [Megalotect (R)]
Children received an anti-CMV immunoglobulin to prevent viral infections
CMV reactivation and infection
The rate of viral reactivation and infection in children undergoing all-HSCT
Time frame: 12 months since allo-HSCT
Overall Survival
The rate of overall survival since allo-HSCT
Time frame: 12 months since allo-HSCT
Hospital stay
The lenght of hospital stay after allo-HSCT
Time frame: 12 months since allo-HSCT
Immunological recovery
The percentage of patients in who the function of CD4+ lymphocytes was restored
Time frame: 12 months since allo-HSCT
GVHD incidence
The percentage of patients who experienced a GVHD
Time frame: 12 months since allo-HSCT
Plan to share: Undecided — Data sharing will be discussed case by case upon reasonable request and after local IRB approval.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.